share_log

Replimune Group Analyst Ratings

Replimune Group Analyst Ratings

Replimune Group分析師評級
Benzinga Analyst Ratings ·  2023/01/05 04:41
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/05/2023 128.57% EF Hutton → $60 Initiates Coverage On → Buy
12/12/2022 166.67% BMO Capital $40 → $70 Maintains Outperform
12/07/2022 29.52% SVB Leerink $30 → $34 Maintains Outperform
11/04/2022 82.86% HC Wainwright & Co. $60 → $48 Maintains Buy
10/14/2022 52.38% BMO Capital $30 → $40 Maintains Outperform
10/03/2022 14.29% SVB Leerink $37 → $30 Maintains Outperform
08/16/2022 63.81% Piper Sandler $44 → $43 Maintains Overweight
08/05/2022 40.95% SVB Leerink $48 → $37 Maintains Outperform
05/24/2022 98.1% Wedbush $59 → $52 Maintains Outperform
05/20/2022 82.86% SVB Leerink $49 → $48 Maintains Outperform
04/04/2022 48.57% JP Morgan $47 → $39 Maintains Overweight
03/18/2022 14.29% BMO Capital $51 → $30 Maintains Outperform
11/19/2021 98.1% Piper Sandler → $52 Initiates Coverage On → Overweight
08/23/2021 86.67% SVB Leerink $55 → $49 Maintains Outperform
08/09/2021 109.52% SVB Leerink $56 → $55 Maintains Outperform
02/05/2021 128.57% HC Wainwright & Co. $58 → $60 Maintains Buy
02/04/2021 113.33% SVB Leerink $57 → $56 Maintains Outperform
11/17/2020 128.57% BTIG → $60 Initiates Coverage On → Buy
11/10/2020 120.95% HC Wainwright & Co. $54 → $58 Maintains Buy
11/06/2020 117.14% BMO Capital $51 → $57 Maintains Outperform
10/15/2020 94.29% BMO Capital $40 → $51 Maintains Outperform
10/15/2020 105.71% HC Wainwright & Co. $25 → $54 Upgrades Neutral → Buy
10/15/2020 67.62% SVB Leerink $27 → $44 Maintains Outperform
08/07/2020 2.86% SVB Leerink $25 → $27 Maintains Outperform
07/01/2020 -4.76% HC Wainwright & Co. → $25 Downgrades Buy → Neutral
06/04/2020 -4.76% HC Wainwright & Co. $24 → $25 Maintains Buy
05/05/2020 -20% Barclays → $21 Initiates Coverage On → Overweight
01/21/2020 -8.57% HC Wainwright & Co. $26 → $24 Maintains Buy
09/04/2019 -23.81% Roth Capital → $20 Initiates Coverage On → Buy
07/23/2019 6.67% Chardan Capital → $28 Initiates Coverage On → Buy
07/12/2019 -0.95% JP Morgan $27 → $26 Upgrades Neutral → Overweight
07/08/2019 -0.95% HC Wainwright & Co. → $26 Initiates Coverage On → Buy
04/25/2019 -8.57% Wedbush → $24 Initiates Coverage On → Outperform
01/23/2019 — JP Morgan Downgrades Overweight → Neutral
08/14/2018 18.1% BMO Capital → $31 Initiates Coverage On → Outperform
08/14/2018 -0.95% JP Morgan → $26 Initiates Coverage On → Overweight
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
01/05/2023 128.57% EF Hutton → $60 開始承保 →購買
12/12/2022 166.67% 蒙特利爾銀行資本 $40 → $70 維護 跑贏大盤
12/07/2022 29.52% SVB Leerink $30 → $34 維護 跑贏大盤
11/04/2022 82.86% HC Wainwright公司 $60 → $48 維護 買
10/14/2022 52.38% 蒙特利爾銀行資本 $30 → $40 維護 跑贏大盤
10/03/2022 14.29% SVB Leerink $37 → $30 維護 跑贏大盤
08/16/2022 63.81% 派珀·桑德勒 $44 → $43 維護 超重
08/05/2022 40.95% SVB Leerink $48 → $37 維護 跑贏大盤
05/24/2022 98.1% 韋德布什 $59 → $52 維護 跑贏大盤
05/20/2022 82.86% SVB Leerink $49 → $48 維護 跑贏大盤
04/04/2022 48.57% 摩根大通 $47 → $39 維護 超重
03/18/2022 14.29% 蒙特利爾銀行資本 $51 → $30 維護 跑贏大盤
11/19/2021 98.1% 派珀·桑德勒 → $52 開始承保 →超重
08/23/2021 86.67% SVB Leerink $55 → $49 維護 跑贏大盤
08/09/2021 109.52% SVB Leerink $56 → $55 維護 跑贏大盤
02/05/2021 128.57% HC Wainwright公司 $58 → $60 維護 買
02/04/2021 113.33% SVB Leerink $57 → $56 維護 跑贏大盤
11/17/2020 128.57% BTIG → $60 開始承保 →購買
11/10/2020 120.95% HC Wainwright公司 $54 → $58 維護 買
11/06/2020 117.14% 蒙特利爾銀行資本 $51 → $57 維護 跑贏大盤
10/15/2020 94.29% 蒙特利爾銀行資本 $40 → $51 維護 跑贏大盤
10/15/2020 105.71% HC Wainwright公司 $25 → $54 升級 中性→購買
10/15/2020 67.62% SVB Leerink $27 → $44 維護 跑贏大盤
08/07/2020 2.86% SVB Leerink $25 → $27 維護 跑贏大盤
07/01/2020 -4.76% HC Wainwright公司 → $25 評級下調 購買→中性
06/04/2020 -4.76% HC Wainwright公司 $24 → $25 維護 買
05/05/2020 -20% 巴克萊 → $21 開始承保 →超重
01/21/2020 -8.57% HC Wainwright公司 $26 → $24 維護 買
09/04/2019 -23.81% 羅斯資本 → $20 開始承保 →購買
07/23/2019 6.67% 查爾丹資本 → $28 開始承保 →購買
07/12/2019 -0.95% 摩根大通 $27 → $26 升級 中性→超重
07/08/2019 -0.95% HC Wainwright公司 → $26 開始承保 →購買
04/25/2019 -8.57% 韋德布什 → $24 開始承保 →跑贏大盤
01/23/2019 — 摩根大通 評級下調 超重→中性
08/14/2018 18.1% 蒙特利爾銀行資本 → $31 開始承保 →跑贏大盤
08/14/2018 -0.95% 摩根大通 → $26 開始承保 →超重

What is the target price for Replimune Group (REPL)?

Replimune Group(REPL)的目標價是多少？

The latest price target for Replimune Group (NASDAQ: REPL) was reported by EF Hutton on January 5, 2023. The analyst firm set a price target for $60.00 expecting REPL to rise to within 12 months (a possible 128.57% upside). 12 analyst firms have reported ratings in the last year.

複製集團(納斯達克：REPL)的最新目標價是由EF Hutton於2023年1月5日報道的。這家分析公司將目標價定為60美元，預計每股收益將在12個月內升至(可能上漲128.57%)。去年有12家分析公司公佈了評級。

What is the most recent analyst rating for Replimune Group (REPL)?

Replimune Group(REPL)的最新分析師評級是多少？

The latest analyst rating for Replimune Group (NASDAQ: REPL) was provided by EF Hutton, and Replimune Group initiated their buy rating.

複製集團(納斯達克代碼：REPL)的最新分析師評級由EF Hutton提供，複製集團啟動了他們的買入評級。

When is the next analyst rating going to be posted or updated for Replimune Group (REPL)?

Replimune Group(REPL)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Replimune Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Replimune Group was filed on January 5, 2023 so you should expect the next rating to be made available sometime around January 5, 2024.

分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與Replimune Group的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Replimune Group的上一次評級是在2023年1月5日提交的，因此您應該預計下一次評級將在2024年1月5日左右提供。

Is the Analyst Rating Replimune Group (REPL) correct?

分析師評級Replimune Group(REPL)正確嗎？

While ratings are subjective and will change, the latest Replimune Group (REPL) rating was a initiated with a price target of $0.00 to $60.00. The current price Replimune Group (REPL) is trading at is $26.25, which is within the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的Replimune Group(REPL)評級是以0.00美元至60.00美元的目標價啟動的。Replimune Group(Replimune Group)目前的交易價格為26.25美元，在分析師的預測範圍內。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論